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Abstract
Background: Hepatitis B virus (HBV) X protein (HBx) reported to be associated with pathogenesis of hepatocellular
carcinoma (HCC) and miR-122 expression is down regulated in HCC. Previous studies reported miR-122 targets
cyclin G1 (CCNG1) expression and this in turn abolishes p53-mediated inhibition of HBV replication. Here we
investigated the involvement of HBx protein in the modulation of miR-122 expression in hepatoblastoma cells.
Methods: Expression of miR-122 was measured in HepG2 cells transfected with HBx plasmid (HBx-HepG2), full length
HBV genome (HBV-HepG2) and in constitutively HBV synthesizing HepG2.2.15 cells. CCNG1 mRNA (a direct target of
miR-122) and protein expressions were also measured in both HBx-HepG2, HBV-HepG2 cells and in HepG2.2.15 cells.
miR-122 expressions were analyzed in HBx-HepG2, HBV-HepG2 and in HepG2.2.15 cells after treatment with HBx mRNA
specific siRNA. Expressions of p53 mRNA and protein which is negatively regulated by CCNG1 were analyzed in HBx
transfected HepG2 cells; X silenced HBx-HepG2 cells and X silenced HepG2.2.15 cells. HBx induced cell proliferation in
HepG2 cells was measured by cell proliferation assay. Flow cytometry was used to evaluate changes in cell
cycle distribution. Expression of cell cycle markers were measured by real time PCR.
Results: Expression of miR-122 was down regulated in HBx-HepG2, HBV-HepG2 and also in HepG2.2.15 cell
line compared to control HepG2 cells. CCNG1 expression was found to be up regulated in HBx-HepG2,
HBV-HepG2 cells and in HepG2.2.15 cells. Following siRNA mediated silencing of HBx expression; increased
miR-122 levels were documented in HBx-HepG2, HBV-HepG2 and in HepG2.2.15 cells. HBx silencing in HBx-HepG2
and HepG2.2.15 cells also resulted in increased p53 expression. FACS analysis and assessment of expressions of cell
cycle markers revealed HBx induced a release from G1/S arrest in HepG2 cells. Further, cell proliferation assay showed
HBx promoted proliferation of HepG2 cell.
Conclusion: Our study revealed that HBx induced down regulation of miR-122 expression that consequently increased
CCNG1 expression. This subsequently caused cell proliferation and release from G1/S arrest in malignant hepatocytes.
The study provides the potential to utilize the HBx-miR-122 interaction as a therapeutic target to limit the development
of HBV related HCC.
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Background
Chronic Hepatitis B virus (HBV) infection serves as a
major etiological factor for the development of hepato-
cellular carcinoma (HCC), a common malignancy world-
wide. The X protein of HBV (also known as HBx) – an
enigmatic and promiscuous viral oncoprotein is known
to be crucially involved in the development of HCC.
HBx alters host gene expression by activating various
cytoplasmic signaling pathways (e.g., NF-kB, SRC, RAS,
PI3K/AKT, JAK/STAT, SMAD and WNT) [1, 2]. HBx
acts a transcriptional transactivator by interacting with
nuclear transcription factors (e.g., CREB, ATF-2, OCT-1,
TBP) and basal transcription factors [3] leading to in-
creased cell proliferation and survival [4]. HBx modu-
lates other cellular processes like reduction of DNA
repair, impairment of p53-mediated apoptosis [5], activa-
tion of mitogen activated protein kinase (MAPK) path-
ways and induction of apoptosis by altering the TNFα
and NF-kB signaling pathways [6–9]. HBx protein may
increase the expression of TERT and telomerase activity,
increasing the natural life of hepatocytes thus transforming
to malignancies [10].
MicroRNAs (miRNAs) are a large family of functional
transcripts in eukaryotic cells [11], which are small,
endogenous, noncoding RNAs (21–23 nucleotides) that
enhance mRNA degradation or inhibit posttranscrip-
tional translation [12]. miR-122 –a liver specific miRNA
exhibits key role in diverse aspects of hepatic function
and pathogenesis [13, 14]. miR-122 are also found to be
involved in neoplastic transformation and tumorigenicity
[15–18]. It shows reduced expression in HCC and HCC-
derived cell lines and culminates in hepatocarcinogenesis
by targeting genes namely CCNG1, SRF, IGF1R, BCL2L2
and ADAM17 [18–20]. A recent study has revealed that
chronic HBV infection is associated with loss of miR-
122 expression, thus contributing to viral replication
and carcinogenesis through CCNG1 modulated p53
activity. Further, HBV mRNA induced miR-122 down
regulation has been shown to up regulate PTTG1- bind-
ing protein, which in turn also stimulates HCC tumor
growth [21, 22].
Evidences are accumulating about the interaction be-
tween HBx protein and miRNAs. HBx protein and the
HBx mRNA are known to act synergistically to repress
miR-15a/16 expression in HepG2 cells through induc-
tion of c-Myc gene [23, 24]. miR-101 is shown to be
down-regulated by the HBx protein and induces aber-
rant DNA methylation by targeting DNA methyl trans-
ferase 3A [25]. A previous study from our lab showed
that HBx protein differentially modulates expression of
miR-222, miR-21 and miR-145 in HepG2.2.15 cells [26].
As host cellular miRNA expressions are modulated
by HBx protein evidenced in hepatic cancer cell line and
chronic HBV infection reduces miR-122 expression,
present study was performed to have an insight into the
possible role of HBx protein of HBV in the modulation of
miR-122 expression in hepatoblastoma cell line. We ob-
served that expression of miR-122 were down- regulated
in HepG2 cell line ectopically expressing HBx and 1.3 fold
HBV genome through transient transfection and also in
HepG2.2.15 cells. miR-122 expression was also reduced in
LC and HCC patients infected with HBV. CCNG1- the
target mRNA and protein of miR- 122, were modulated
accordingly during transient transfection of HepG2 and in
stable HBV producing cell line. miR-122 expression can
be restored after HBx–siRNA treatment. Further, FACS
analysis and cell proliferation assay showed HBx induced




The hepatoblastoma cell line HepG2 was maintained in
Dulbecco’s modified Eagle medium (DMEM) with 10 %
fetal bovine serum (Sigma Aldrich, Munich, Germany)
at 37 °C in a humidified atmosphere with 5 % CO2. At
approximately 80 % cell confluency, cells were harvested
for RNA isolation. HepG2.2.15 cells, which are a kind
gift of Dr. Tatsuo Kanda, Japan, were maintained in the
RPMI1640 medium with 12 % fetal bovine serum in a
37 °C in a humidified atmosphere with 5 % CO2. The
cells were generated every three days, and could be used
when HBV DNA was detected stably in the supernatant.
Study subjects
The patients recruited in this study were admitted to the
SCB Medical College of Odisha, India from February
2013 to April 2014. A total of 102 advanced liver disease
patients were recruited in this study which includes two
groups: those with liver cirrhosis (LC) and those with
hepatocellular carcinoma (HCC). These patients were
screened for presence of HBV DNA and 57 were found
to be HBV DNA positive. Finally 34 patients were se-
lected having age group of 35–50 years. Age and sex
matched 26 healthy individuals were enlisted as normal
controls. The expression of miRNA- 122 was first com-
pared between sera of advanced liver disease patients
and healthy individuals (control). Subsequently advanced
liver disease patients were subdivided to LC and HCC
patients to indicate the significance of miRNA expres-
sion variation in these 2 distinct clinical groups.
The signed informed consent was obtained from all
the study subjects and the study protocol was approved
by Kalinga Gastroenterology Foundation, Odisha ethical
committee. Patient samples were assigned on arbitrary
identification based on the order of enrollment in our
study. Study subjects were free of other viral infections,
including human immunodeficiency virus (HIV), hepatitis
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C virus (HCV). Control samples were obtained from vol-
untary blood donors negative for HIV, HBV and HCV.
Plasmids and RNA oligonucleotides
HBx plasmid -pCXN2-HBx was gifted by Dr. Tatsuo
Kanda, Japan. 1.3 fold full length HBV genome cloned
into pUC 19 vector was a gift of Dr. Mashashi Mizo-
kami, Japan. HBx-siRNA [27] was used to produce small
interfering RNAs (siRNAs) targeting HBx mRNA
(Ambion, Texas, USA). siRNA duplexes with non-
specific sequences were taken as negative control (NC)
for siRNA experiments. siRNA transfection was carried
out using Lipofecatmine 2000 (Invitrogen, Carlsbad, CA,
USA) reagent and medium was replaced 6 h after trans-
fection. RNA were extracted following different time
interval.
Cell transfection
Transfection was performed using Lipofecatmine 2000
(Invitrogen) following manufacturer’s instructions. Briefly,
twenty four hours prior to transfection 5 × 105 HepG2
cells were seeded into a six well plate. Cells were trans-
fected with two doses - 1 μg and 2 μg of pCXN2-HBx
plasmid, 1.3 fold HBV plasmid (puC19-1.3 HBV) and
empty vector. In case of HBx and HBV plasmid trans-
fection, after 48 h, cells were used for RNA extraction.
For siRNA experiments RNA were extracted 48 h post
transfection.
RNA isolation from hepatoblastoma cells
Total RNA was extracted using Trizol reagent (Invitrogen)
from 1 × 106 ~ 2 × 106 cells according to manufacturer’s
protocol.
cDNA synthesis and quantitative mRNA expression by
real-time PCR
Reverse transcription was performed using the RevertAid
first-strand cDNA synthesis kit following the manufac-
turer’s instructions (MBI Fermentas, Vilnius, Lithuania).
RNA quantity and quality were assessed by determination
of the optical density at 260 and 280 nm using spec-
trophotometry and additionally by visualization in
agarose gels. Real-time PCR was performed in the ABI
7000 SDS (Applied Biosystems) using the Power SYBR
Green (Applied Biosystems) according to the manu-
facturer’s instructions. The thermal cycling conditions
comprised of 5 min incubation at 95 °C, followed by
40 cycles at 95 °C for 15 s, 60 °C for 30 s. All of the re-
actions were performed in triplicate. The relative
quantity of the target mRNA was normalized to the
level of the internal control GAPDH mRNA level. The
relative quantitative analyses of the data were per-
formed using SDS 7000 system software v1.2.3 (Ap-
plied Biosystems, USA). The relative quantitation of
target gene expression was obtained using the com-
parative ΔΔCT method [28].
Western blot analysis
After 48 h of transfection, proteins were prepared for
western blot analysis. Cells were washed in cold PBS
and cellular proteins were extracted by using NP-40
buffer for 30 mins at 4 °C. Lysates were cleared by
centrifugation and proteins were separated by gel elec-
trophoresis. Membranes were blocked in TBS-0.1 %
Tween 20 (TBS-T)/5 % (w/v) milk for 1 h at room
temperature. Membranes were then incubated with pri-
mary antibodies diluted in TBS-T for 4 h at room
temperature. Subsequently, membranes were washed with
TBS-T and incubated with peroxidase-conjugated second-
ary antibody diluted in TBS-T at room temperature for 30
mins. Membranes were washed in TBS-T and bound anti-
bodies were detected by enhanced chemiluminescence
Reagents (Amersham Biosciences, Buckinghamshire, UK).
Primary antibodies used were anti-cyclin G1, anti-p53 and
anti-β-actin (Santa Cruz, USA). Proteins bands were
quantified using a Densitometry scanner (Bio-Rad-GS-
800, USA).
miRNA assay
Approximately 35 ng of total RNA was reverse-tran-
scribed in a 10-uL volume using the TaqMan miRNA
reverse-transcriptase kit (Applied Biosystems, Foster City,
CA) according to the manufacturer’s recommendations.
Three microliters of the reverse-transcription reaction
was used in each of the real-time PCR assays. Analyses
of miR-122 were carried out in triplicates by means of
the TaqMan human miRNA assays (Applied Biosys-
tems) using SDS 7000 system software v1.2.3 (Applied
Biosystems, USA).
Cell proliferation assay
Cell proliferation was measured by Cell Titer 96 Aque-
ous One Solution Cell Proliferation Assay (Promega,
USA), an MTT assay. Briefly, 3 × 103 viable cells were
counted in a hemocytometer using trypan blue. The cells
were uniformly seeded in each well of 96-well plates and
grown in 100 μl DMEM supplemented with 5 % FBS.
After 24 h, when a semi confluent monolayer is ob-
tained, HepG2 cells were transfected with HBx plasmid
and empty vector; co transfected with HBx plasmid and
HBx-siRNA. The plates were incubated at 37 °C in a hu-
midified atmosphere of 5 % CO2 for another 48 h. Next,
cells were suspended by trypsinization. Relative cell
numbers were determined by incubating cells with MTT
for 4 h. The resulting formazan was dissolved in DMSO
and was measured at 490 nm in spectrophotometer
(SpectraMax M2 Multi-Mode Microplate Reader). The
absorbance at 490 nm is directly proportional to the
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number of viable cells. All experiments were performed
in quadruplets.
Cell cycle analysis
For cell cycle analysis, cells were harvested and thor-
oughly re-suspended in Phosphate Buffered Saline (PBS).
The cells were then fixed by adding double volume of
chilled 100 % ethanol (Merck), drop wise, with continu-
ous vortexing. After incubating the mixture overnight
at −20 °C, it was spun and the cells were re suspended
in 500 μl of PBS. Cells were then incubated with RNaseA
(0.2 mg/ml) for 30 mins followed by Propidium Iodide
(50 μg/ml) (Sigma) at 37 °C for 1 h. Flow cytometric
data acquisition was performed on the BD FACS
Calibur platform.
Statistical analysis
All statistical analyses were performed by using Graph-
Pad Prism v.5.0 (GraphPad Software, USA). Data from
three independent experiments were expressed as the
mean ± SD. T-test (unpaired, two-tailed) was used for
comparison. Probability levels of P < 0.001, P < 0.01 and
P <0.05 were set for the determination of statistical
significance.
Results
miR-122 expression is significantly decreased in
transiently transfected and constitutively HBV producing
hepatoblastoma cells and in HCC patients infected with HBV
HepG2 cells were used for transient transfection to
understand the possible impact of HBx on host miRNA
expression. HepG2 cells were transfected with HBx plas-
mid (pCXN2-HBx) and 1.3 fold HBV genome (puC19-
1.3 HBV). HepG2 cells were also transfected with empty
expression vectors (pCXN2 and pUC19) and the expres-
sion pattern of miR-122 was measured in HBx trans-
fected HepG2 cells. Interestingly, miR-122 was found to
be significantly down regulated (P < 0.001) in HBx trans-
fected cells, compared to the HepG2 cells transfected
with empty expression vector (Fig. 1a). The expression
was normalized by using RNU6 as internal control. The
comparison of the fold changes measured during down
regulation of miR-122 in HBx transfected HepG2 cells
and in empty vector transfected HepG2 cells is pre-
sented in Table 1. Transfection with two different doses
of HBx plasmid, however, did not exhibit any dose
dependent down regulation.
Transfection of HepG2 cells by 1.3 fold HBV genome,
supported our previous experiments. Here also, we found
significantly reduced (P < 0.001) levels of miR-122 expres-
sion in HBV transfected cells, compared to HepG2 cells
transfected with empty pUC19 vector (Fig. 1b). When we
measured the expression of this miRNA in HepG2.2.15
cells, which is a stable HBV producing cell line, we found
that expression of mR-122 was significantly down reg-
ulated (P < 0.01) in comparison to the control HepG2
cells (Fig. 1c).
Next, miR-122 expression was analyzed in the sera of
advanced liver disease patients infected with HBV. It
was revealed that miR-122 expression was decreased
significantly (P <0.001) in the sera of advanced liver dis-
ease patients when these patients were compared with
healthy controls (Fig. 1d). This reduced expression of miR-
122 was reflected in both LC and HCC patient groups
when these two groups were compared separately with
healthy controls (Fig. 1e). Interestingly, the comparison in-
dicated that the HCC patients had lower miR-122 expres-
sion (P <0.001) than LC patients.
Expression of target gene at mRNA and protein level
due to transient transfection by HBx and in stable HBV
producing cell
Transfection of HepG2 cells by HBx caused up regula-
tion of target mRNA CCNG1 expression compared to
control cell line, i.e. transfected with empty expression
vector (Fig. 2a). Transfection of HepG2 cells with 1.3
fold HBV genome revealed the same result as we ob-
served in HBx transfected HepG2 cells. CCNG1 was
found up regulated in 1.3 fold HBV genome transfected
HepG2 cells when compared with HepG2 cells trans-
fected with empty pUC19 vector (Fig. 2b). In both the
cases (Fig. 2a, b) the up regulations of CCNG1 mRNA
were significant (P <0.001). In case of HepG2.2.15 cell
line, the CCNG1 expression was significantly elevated
(P < 0.01) as compared to the control HepG2 cells
(Fig. 2c). Expression of GAPDH was measured as
internal control.
Western blot analysis confirmed that transfection by
HBx caused up regulation of the target protein i.e.
CCNG1 expression in HepG2 cells compared to control
cell line. (Fig. 2d). When we transfected HepG2 cells
with full length HBV genome, CCNG1 expression was
found to be higher in HBV transfected cells than empty
vector transfected HepG2 cells (Fig. 2e). Further, we
compared target protein expression in HepG2.2.15 cell
line and its control cell HepG2. We observed that
CCNG1 was overexpressed in HepG2.2.15 cells in com-
parison to control HepG2 cells (Fig. 2f ). This result was
consistent with experimental results observed with
miRNA expression in HBx or HBV transfected HepG2
cells. Expression of β-actin was considered as endogenous
control in these experiments.
HBx modulated miR-122 expression as revealed by RNA
interference study
HepG2 cells were co transfected with HBx plasmid; 1.3
fold full length HBV genome and HBV X gene specific
siRNA to knock down the HBx mRNA. HepG2.2.15 cells
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were also transfected with HBx siRNA. RNA was ex-
tracted at 48 h, post siRNA treatment. Both in HBx
transfected and 1.3 fold HBV transfected HepG2 cells,
significantly elevated expression (P < 0.01) of miR-122 was
observed in 48 h post siRNA treatment (Fig. 3a, b). In
HepG2.2.15 cell line, after 48 h post transfection, expres-
sion of miR-122 was reestablished (P < 0.05) (Fig. 3c).
Silencing of HBx increases p53 mRNA and protein level in
HBx transfected HepG2 and HepG2.2.15 cell line
miR-122 increases p53 protein levels and activity
through its negative regulation of CCNG1. Further, from
our experiments we observed that HBx suppressed miR-
122 expression and consequently up regulated expres-
sion of CCNG1. These two observations were very likely
interrelated. As such, we decided to assess the modula-
tion of p53 mRNA and protein level in HBx transfected
HepG2 and HepG2.2.15 cells after knockdown of HBx.
We observed that p53 mRNA and protein levels were
Table 1 The fold changes (log2 values) during down regulation
for miRNA- 122 in HBx transfected HepG2 cells compared to
HepG2 cells transfected with empty expression vector
miRNA HepG2 transfected with
HBx plasmid (1 μg DNA)
HepG2 transfected with
HBx plasmid (2 μg DNA)
miR-122 −0.17 −0.3
Fig. 1 miR-122 expression is modulated by HBx in hepatoblastoma cells in vitro. a The relative expression of miR-122 in HepG2 cells transiently
transfected with HBx expressing plasmid PCXN2-HBx or control vector. Cells are transfected with 1 μg and 2 μg of HBx plasmid respectively or
pCXN2 as a control. b The relative expression of miR-122 in HepG2 cells transiently transfected with 1.3 fold full length HBV genome cloned into
pUC19 plasmid or control vector. The cells are transfected with 1 μg pUC19-HBV or 1 μg pUC19. c The relative expression of miR-122 in constitu-
tively HBV producing HepG2.2.15 cell line or control HepG2 cells. Cells were collected for analysis 48 h after each transfection. The miRNA expres-
sions were measured by qRT-PCR. Plotted are the mean ± SD of three samples normalized to U6 expression (*P < 0.05, **P < 0.01, ***P < 0.001;
Student’s t-test). d Real-time PCR analysis of miR-122 expression from patient serum samples. The miRNA levels in healthy controls were arbitrarily set
as 1.0 and compared with advanced liver disease patients. e Comparison of miR-122 expression between healthy controls, LC and HCC patients. RNA
was isolated from serum samples using miRVANA small RNA isolation assay and assayed using the TaqMan miRNA kit. The results were normalized to
RNU6 endogenous control. Experiments were performed in triplicate. Error bars are means of ± standard deviation (SD). Mann–Whitney U test was
performed to determine P-values (*P < 0.05, **P < 0.01, ***P < 0.001). LC = liver cirrhosis; HCC = Hepatocellular carcinoma
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reduced significantly in HBx transfected HepG2 cells
(P < 0.01) (Fig. 4a, d). Interestingly, HBx knockdown
in HBx transfected HepG2 and HepG2.2.15 cells resulted
in increased expression of p53 mRNA and protein com-
pared to their negative controls (P < 0.01) (Fig. 4b, e, c f
respectively).
HBx induces cell proliferation through modulation of
miR-122 and CCNG1 interaction
We noted that HBx transfected HepG2 cells exhibited
increased CCNG1 expression accompanied by a de-
crease of p53 mRNA and protein expression. Since
CCNG1 has a role in cellular growth control, these re-
sults prompted us to verify involvement of HBx protein
in cell proliferation and subsequent changes in the cell
cycle through HBx induced modulation of miR-122–
CCNG1 interaction.
We assayed the distribution of cells in the different
phases of the cell cycle by flow cytometry analysis. The
percentage of cells in different phases of the cell cycle
was compared between HBx transfected HepG2 cells
and cells transfected with empty plasmid (Fig. 5a).
Though the proportion of cells was higher in G1 phase
compared to S and G2/M phases, we observed that
transfection of HBx plasmid in HepG2 cells induced a
release from G1/S arrest. An increase in the G2/M phase
cell population in HBx transfected HepG2 cells was evi-
dent, when compared to cells transfected with empty
plasmid. In order to corroborate the impact of HBx pro-







Fig. 2 HBx modulated expression of target mRNA and protein CCNG1 (cyclin G1) in hepatoblastoma cells. a Relative expression of CCNG1
mRNA– target of miR-122 in HBx transfected HepG2 cells. Cells are transfected with 1 μg and 2 μg of pCXN2-HBx respectively or pCXN2 as a con-
trol. b Relative expression of CCNG1 mRNA in 1.3 fold full length HBV genome transfected HepG2 cells. Cells are transfected with 1 μg pUC19-
HBV or 1 μg pUC19 control vector. c Relative expression of CCNG1 mRNA in HepG2.2.15 cell line and in control HepG2 cells. RNA were ex-
tracted 48 h post transfection. The mRNA expressions were measured by qRT-PCR and the expressions were normalized to GAPDH. Data are
expressed as the mean ± SD from three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test). d Western blot confirmed
protein cyclin G1 was increased accordingly in HBx transfected HepG2 cells. HepG2 cells are transfected with 1 μg and 2 μg of pCXN2-HBx respect-
ively or empty pCXN2 as a control. e Expression of cyclin G1 protein in 1.3 fold HBV transfected HepG2 cells. HepG2 cells are transfected with 1 μg
pUC19-HBV or 1 μg pUC19 vector as a control. f Expression of cyclin G1 in constitutively HBV producing HepG2.2.15 and control HepG2 cell line. Cells
were collected for protein analysis 48 h after each transfection. β actin was taken as endogenous control. Protein bands were quantified using Densito-
metric scanner (Bio-Rad). Below are the graphical representations of intensity ratio between target protein cyclin G1 and β actin in each lane
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cycle, we further investigated its effect on the expression
of cell cycle genes. As mentioned previously, the analysis
of HBx transfected HepG2 cells indicated reduced levels
of p53 mRNA as well as protein, which is one of the key
regulators in the transition from G1 to S phase. In con-
trast, p53 mRNA and protein were found to increase
when X was silenced in HBx transfected HepG2 and
HepG2.2.15 cells. Another protein, p21 is known to be
an important regulator of cell cycle progression at G1
and S phase and its expression is specifically controlled
by p53 protein. Interestingly, in the HBx transfected
HepG2 cells, expression of p21 transcripts was signifi-
cantly lower (P < 0.001) as compared to control cells and
its expression was increased significantly (P < 0.05) in
HBx transfected HepG2 and HepG2.2.15 cells when
both the cells were treated with HBx siRNA (Fig. 5b).
Expression of CCND1 (cyclin D1) remains high during
G1 to S phase transition in the cell cycle. Transfection
of HepG2 cells with X gene led to significantly increased
(P < 0.01) expression of CCND1 RNA compared to con-
trol cells. Its expression was found to decrease when
HBx transfected HepG2 (P < 0.05) and HepG2.2.15 cells
were treated with HBx – siRNA (Fig. 5c). CCNE1 (Cyc-
lin E), another important regulator of G1/S transition,
remained up regulated in HBx transfected HepG2 cells
where as it remained down regulated in X silenced HBx-
HepG2 cells (P < 0.05) and HepG2.2.15 cells (Fig. 5d).
We observed there was a release from G1/S arrest
and a marked alteration of cell cycle regulators for G1/
S phase in HBx transfected HepG2 cells. Reduction of
the relative proportion of cell populations in S phase
and visible increase in G2/M phase was also evident in
those cells. In order to find out whether the cells were
at G2 arrest or at M phase, we assessed the expression
of G2/M markers. In HBx transfected HepG2 cells we
found significantly increased level of CCNB1 (cyclin B)
expression (P < 0.001) whereas in HBx silenced HepG2
cells and HepG2.2.15 cells (P < 0.01), its expression was
found to be down regulated (Fig. 6a). We also examined
another G2/M marker, CDC25A, a member of CDC25
family of M phase inducer phosphatase. In HBx trans-
fected HepG2 cells a significantly increased level of
CDC25A expression (P < 0.01) was observed compared
to control cells. CDC25A expression was found to de-
crease in HBx- HepG2 cells and HepG2.2.15 cells (P <
0.05) when these cells were treated with HBx-siRNA
(Fig. 6b). Apart from CCNB1 and CDC25A, we also
studied the expression profile of CCNA1 (cyclin A),
which acts on G2/M transition, in addition to its regu-
lation of the S phase. We noticed decreased expression
of CCNA1 in HBx transfected HepG2 cells (P < 0.01)
and increased expression of CCNA1 in X silenced HBx-
HepG2 cells and HepG2.2.15 cells (P < 0.01) (Fig. 6c).
This reduced expression of CCNA1 is consistent with
high expression of CCNB1- the mitotic marker, as
observed in HBx transfected HepG2 cells.
Further we performed an MTT assay to measure the cell
proliferation. After 48 h of transfection, HepG2 cells trans-
fected with HBx plasmid exhibited significant (P < 0.05) cell
proliferation compared to its control cell (Fig. 6d). Interest-
ingly, when HepG2 cells were co transfected with HBx
plasmid and HBx siRNA, we observed the reverse scenario
i.e. cell proliferation was reduced in HBx silenced HepG2
cells than its negative control (Fig. 6e).
Fig. 3 Restoration of miRNA expression after RNA interference study. a Relative expression of miR-122 in HepG2 cells by co-transfection with HBx
plasmid (0.8 μg) and HBx mRNA specific siRNA (40 p mole) or Negative Control. b Relative expressions of miR-122 was measured when HepG2
cells were co-transfected with 1.3 fold full length HBV genome (0.8 μg) and HBx mRNA specific siRNA (40 p mole) or Negative Control. c HepG2.2.15
cells were transfected with HBx siRNA (80 p mole) or Negative Control and relative expressions of miR-122 was measured. Data plotted
are the mean ± SD normalized to RNU6 expression. The experiments were performed in triplicate (*P < 0.05, **P < 0.01, ***P < 0.001; Student’s
t-test). RNA were collected 48 h after each transfection
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Discussion
Hepatitis B virus X protein is often referred to as an
onco protein as it interacts and modulates the expres-
sion of cellular genes, which in turn alter the cell signal-
ing and other cellular processes. HBx induces persistent
changes in different cellular genes that subsequently
provide a signal to hepatocytes for growth and prolifera-
tion thus leading to the development of hepatocellular
carcinoma [29–32]. Involvement of microRNA is being
uncovered in almost all aspects of cancer biology, such
as proliferation, tumorigenesis, apoptosis, invasion/me-
tastasis and angiogenesis [33, 34]. The expression of
tumor suppressor miR- 122 is often found down regu-
lated in hepatocellular carcinoma and chronic HBV pa-
tients as also in HCC derived cell lines. Our study
demonstrated involvement of HBx protein in the modu-
lation of miR-122 expression in hepatoblastoma cell
lines. We have taken CCNG1 as the reported target of
miR- 122.
It has been documented that miR-122 is abundant in
liver and is characteristically down regulated in 70 % of
HCCs [18, 35]. Our study on HBV infected patients with
different clinical outcomes (advanced liver disease pa-
tients or its subset LC and HCC patients) demonstrated
a b c
d e f
Fig. 4 p53 mRNA and protein expression in HBx transfected HepG2 and HepG2.2.15 cells after RNAi treatment. a Relative expression of p53 in
HepG2 cells after transfection with HBx expressing plasmid pCXN2-HBx or control vector. Cells are transfected with 1 μg of HBx plasmid or pCXN2
as a control. RNA were collected 48 h after each transfection. b Relative expression of p53 in HepG2 cells by co-transfection with HBx plasmid
(0.8 μg) and HBx mRNA specific siRNA (40 p mole) or Negative Control. RNA were collected 48 h after each transfection. c HepG2.2.15
cells were transfected with HBx siRNA (80 p mole) or Negative Control and relative expressions of p53 was measured. RNA were collected
24 h post transfection. Data plotted are the mean ± SD normalized to GAPDH expression. The experiments were performed in triplicate
(*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test). d Corresponding p53 protein expression was analysed by western blot in HepG2 cells
transfected with 1 μg of HBx plasmid or empty vector as a control. e p53 protein expression was analysed in HBx silenced HepG2 cells
transfected with HBx plasmid. HepG2 cells were co-transfected with HBx plasmid (0.8 μg) and HBx mRNA specific siRNA (40 p mole) or
Negative Control f Relative Expression of p53 protein was measured in HepG2.2.15 cells after siRNA treatment. HepG2.2.15 cells were transfected with
HBx siRNA (80 p mole) or Negative Control. Cells were collected for protein analysis 48 h after each transfection. For HepG2.2.1.5, cells were collected
at 24 h post transfection. β actin was taken as endogenous control. Protein bands were quantified using Densitometric scanner (Bio-Rad). Below are
the graphical representations of intensity ratio between p53 and β actin in each lane
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that miR-122 expression was decreased, as compared to
healthy controls. As mentioned, CCNG1 is the target of
miR-122 and an inverse relation exists between them in
HCC derived cell lines and HCC tissues. CCNG1 is the
only known cyclin that bears two functional binding
sites for p53 tumor suppressor protein and is transcrip-
tionally triggered by this transcription factor. Several
groups have reported that HBx proteins interact directly
with p53 as the binding region of p53 is located within
the transactivation domain of HBx protein [5]. In trans-
genic mice that express HBx, tumor development corre-
lates precisely with the binding of p53 to HBx in the
cytoplasm and causes complete impediment of the
translocation of p53 to the nucleus [36]. miR-122 was
shown to increase p53 protein levels and activity
through its negative regulation of cyclin G1 [16]. Cyclin
G1 forms a complex with PP2A phosphatase and en-
hances MDM2 activity to inhibit p53 [37]. By directly
repressing the expression of CCNG1, miR-122 increases
p53 protein levels and activity and inhibits tumorigenesis
in liver cancer. We observed miR-122 expression is re-
duced and cyclin G1 protein expression is elevated in
HBx transfected HepG2 cells. We also noticed p53
mRNA and protein levels were decreased in HBx trans-
fected HepG2 cells. Conversely, silencing of HBx mRNA
in HBx transfected HepG2 and HepG2.2.15 cells re-
vealed an increase in p53 mRNA and protein expression.
In this light, our results suggest that HBx protein caused
down regulation of miR-122 that induce up regulation of
CCNG1 in HepG2 cells which produce hindrance to the
activity of p53 protein. In addition, reduced level of
miR-122 and elevated level of CCNG1expression was
noted in HBV genome transfected HepG2 cells and in
HepG2.2.15 cells. Moreover, HBx siRNA treatment in
transiently transfected HepG2 cells and in HepG2.2.15
cells rescued miR-122 expression.
Our data suggested that transfection of HBx in HepG2
cells suppressed miR-122 expression which in-turn in-
duced increased expression of cyclin G1. Involvement of
cyclin G1 in cellular growth control still remains contro-
versial, however it has been observed to be involved in
the G2/M arrest in response to DNA damage, suggesting
its growth inhibitory activity [38]. On the other hand,
several reports indicate a cellular growth promoting ac-
tivity for cyclin G1, since overexpressed cyclin G1 in-
creases cell growth of cancer cells [39] and its silencing
reduces cell proliferation [40]. Increased levels of
CCNG1 were found in several human tumours such as
breast cancer and osteosarcoma [41, 42]. In the present
study, flow cytometry analysis revealed that transfection
of HBx plasmid in HepG2 cells induced a release from
G1/S arrest. We also found several markers for G1/S
phase transition to be modulated in these cells. Interest-
ingly, several lines of evidence have demonstrated that
Fig. 5 Flow cytometric analysis and alteration of cell cycle regulators upon HBx transfection. a Graphical representation of percentage of cells in
different phases of cell cycle compared between HepG2 cells transfected with HBx plasmid or empty expression vector as described above. b. c.
d. Alteration of cell cycle regulators in HepG2 and HepG2.2.15 cells. Relative mRNA expressions of different cell cycle regulators were compared
between HepG2 cells transfected with HBx plasmid and empty vector; X silenced HBx transfected HepG2 cells and negative control; HBx silenced
HepG2.2.15 cells and negative control. b Relative p21 expression (c) Relative CCND1 expression (d) Relative CCNE1 expression
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HBx accelerated the release of cells from G0/G1 and
their entry into S phase by enabling a rapid activation of
CDK2 kinase activity [43]. HBx mediated stimulation of
Src kinases and activation of cyclin A- CDK2 complexes
was found to force growth-arrested cells to transit
through G1 phase [29].
We found increased population of HBx transfected
HepG2 cells to be in the G2/M phase by flow cytometry
analysis. Whether cells were at G2 arrest or at mitotic
divisional phase sorted out by studying G2/M markers
and cell proliferation assay, which revealed HBx trans-
fected HepG2 cells are in active divisional phase and this
ectopic expression of HBx induced proliferation of these
cells. In line with previous reports supporting the growth
promoting function of CCNG1, our study demonstrated
that HBx evoked increased CCNG1 expression as a re-
sult of miR-122 suppression which enhanced
proliferation of HepG2 cells.
Li et al. [44] demonstrated that all four HBV mRNAs
bear a complimentary miR-122 sequence which act as
sponges to bind and sequester endogenous miR-122.
This study suggested HBV transcripts are involved in
HBV-mediated miR-122 suppression. Very recently Liang
et al. [45] showed that HBx-LINE1, a hybrid RNA tran-
script originating from human LINE1 and the HBV X
gene, consists of six miR-122-binding sites and enforced
expression of HBx-LINE1 successfully exhausted cellular
miR-122 expression thereby promoting mouse hepatic in-
jury and EMT-like changes in liver cell. Development of
hepatic cancer is a multistep process and involves multi-
factorial etiology. Apart from modulation of a number of
cell signaling pathways, different genetic and epigenetic
factors are altered in HBV associated hepatocellular car-
cinoma. A previous study by Song et al. [46] established
that HBx binds to PPARc and prevents the transcription
of miR-122. Peng et al. [47] revealed that reduction of
Gld2 level mediated by HBx resulted in down-regulation
of miR-122. Multiple regulatory mechanisms may coexist
in HBV-infected cells that control miR-122 levels. Our
study provided evidence of HBx-miR-122- CCNG1/p53
mediated induction of cell proliferation that may culmin-
ate into hepatic cancer (Fig. 7).
Conclusions
In conclusion, our study indicated that the HBx protein
of HBV induced down regulation of highly abundant
Fig. 6 HBx promoted cell proliferation in HepG2 cells. a. b. c. Alteration of G2/M markers in HepG2 and HepG2.2.15 cells. Relative mRNA
expressions of different cell cycle regulators were compared between HepG2 cells transfected with HBx plasmid and empty vector; X
silenced HBx transfected HepG2 cells and negative control; HBx silenced HepG2.2.15 cells and negative control. a Relative CCNB1 expression (b) Relative
CDC25A expression (c) Relative CCNA1 expression. d. e Cell proliferation assay in HBx transfected HepG2 cells and X silenced HBx transfected HepG2 cells
at the 48 h time-point. d Results from MTT assay showed that HBx transfection led to a significant increase in HepG2 cell proliferation compared with
control cells (e). Cell proliferation was decreased in X silenced HBx - HepG2 cells compared to negative control. Data shown represent the mean ± SD.
The experiments were performed in quadruplet (*P < 0.05; Student’s t-test)
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liver specific miR-122 in hepatoblastoma cells. HBx
mediated suppression of miR-122 enhanced cell prolifer-
ation of HepG2 through cyclin G1-p53 mediated path-
way. The outcome of this study expands our
knowledge about complex host viral interactions lead-
ing to alteration of cellular genes, culminating in hepatic
proliferation. Furthermore, this study also provides a po-
tential therapeutic target for utilizing the HBx - miR-122
interaction as an effective strategy for management of
HBV related HCC.
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